Concepedia

Author

Ghayas C. Issa

The University of Texas MD Anderson Cancer Center

Also Known As

Ghayas C Issa, Ghayas C. Issa, Ghayas Issa, Ghayas C. Issa

82

Publications

3.8K

Citations

16

H-Index

20

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterHarvard UniversityAugusta University HealthDana-Farber Cancer InstituteCancer Research And Biostatistics
GC

About

Ghayas C. Issa is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

3K

2

Immunology

3

3

3K

3

Cell Biology

2

2

3K

4

Pathology

2

2

187

5

Health Sciences

1

1

171

Ghayas C. Issa

×

17

Publications

3.5K

Citations

14

H-Index

YearCitations

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux,

Cell

2011

2.8K

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

Kiyomi Morita, Hagop M. Kantarjian, Feng Wang,

Journal of Clinical Oncology

2018

182

Prognostic and therapeutic impacts of mutant <i>TP53</i> variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short, Guillermo Montalban‐Bravo, Hyunsoo Hwang,

Blood Advances

2020

171

Venetoclax combined with <scp>FLAG‐IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia

Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi,

American Journal of Hematology

2022

87

Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia

Antonio Sacco, Monette Aujay, Brittany Morgan,

Clinical Cancer Research

2011

44

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Nicholas J. Short, Keyur P. Patel, Maher Albitar,

Blood Advances

2020

40

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Nicholas J. Short, Hind Rafei, Naval Daver,

Blood Advances

2020

35

Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)

Gautam Borthakur, Jörge E. Cortes, Farhad Ravandi,

Blood

2019

25

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Tapan M. Kadia, Gautam Borthakur, Naveen Pemmaraju,

Blood

2020

22

Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study

Álex Bataller, Guillermo Montalban‐Bravo, Alexandre Bazinet,

The Lancet Haematology

2024

19

Page 1